Press coverage about Corium International (NASDAQ:CORI) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corium International earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.5481083943147 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Corium International (CORI) opened at $11.59 on Monday. Corium International has a 1-year low of $2.67 and a 1-year high of $12.32. The company has a debt-to-equity ratio of 1.89, a quick ratio of 6.80 and a current ratio of 7.04.

Several analysts have weighed in on CORI shares. BidaskClub raised Corium International from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Zacks Investment Research cut Corium International from a “buy” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine cut Corium International from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Corium International in a report on Sunday, September 17th. Finally, HC Wainwright started coverage on Corium International in a report on Tuesday, September 26th. They issued a “buy” rating and a $15.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Corium International has an average rating of “Buy” and an average target price of $13.00.

In other news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $11.05, for a total transaction of $1,657,500.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 868,100 shares of company stock worth $9,538,781 over the last quarter. Corporate insiders own 45.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Corium International (CORI) Stock Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.